Lucid Capital initiated coverage of Medicenna Therapeutics (MDNAF) with a Buy rating and C$4 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDNAF:
- Promising Developments in Medicenna Therapeutics Corp’s ABILITY-1 Trial Justify Buy Rating
- Medicenna to Engage Investors at ROTH Healthcare Conference
- Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates
- Medicenna to Present at H.C. Wainwright Global Investment Conference